This is just for the benefit of jetmanbash who constantly conflated the risks of 24 hour steroid prophylaxis with chronic steroid use. Additional Apollo data for Patisaran, with post hoc analyses suggesting improved survival also demonstrated:
The IONS hope is that Patisaran won't have 80% market share but more like 50-50. They are deluded. I would be surprised if they get 20% market share, IF, they get approved. Hard to approve a drug that is less safe and less efficacious at the same time as another drug that is bettwer on both counts.